Antidepressants Market Report 2025

The antidepressants market size has grown steadily in recent years. It will grow from $17.11 billion in 2024 to $17.82 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing prevalence of mental health disorders, growing awareness and reduced stigma, advancements in diagnostic practices, expansion of treatment options, government initiatives and mental health policies.

The antidepressants market size is expected to see steady growth in the next few years. It will grow to $20.25 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to rising mental health awareness and advocacy, global impact of stress and lifestyle changes, integration of mental health services, research and development in psychiatry, telemedicine and remote mental health services. Major trends in the forecast period include regulatory changes, market competition, generic market growth, focus on side effect profiles, emerging markets.

The global surge in mental health disorders is a pivotal factor contributing to the expansion of the antidepressant drug industry, with a considerable number of individuals relying on these medications to address conditions such as depression, anxiety disorders, and various mental illnesses. Antidepressant drugs find application in treating a spectrum of disorders, including OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. The prevalence of depression globally ranges from 2% to 6%, with the elderly facing a higher risk compared to other age groups. According to the World Health Organization (WHO), approximately 280 million people worldwide suffered from depression in 2023, highlighting the escalating cases of mental health disorders as a driving force for the antidepressant market.

The rising prevalence of mental illness is anticipated to drive demand for the antidepressants market in the future. Mental illnesses are disorders that affect how individuals think, feel, behave, or believe, often arising from distress or challenges in functioning within social, work, or family settings. Antidepressants are medications used to treat a range of mental health issues, including depression, anxiety, and mood disorders. They function by increasing the levels of specific chemicals in the brain that regulate mood and emotions. For example, in November 2022, the National Health Service, a UK government agency, reported that the prevalence of probable mental disorders among individuals aged 17 to 19 rose from 1 in 6 (17.4%) in 2021 to 1 in 4 (25.7%) in 2022. Thus, the growing incidence of mental illness is set to propel the antidepressants market.

A noteworthy trend in the antidepressant market is the treatment of resistant depression, with ketamine emerging as a novel therapeutic approach. Ketamine, initially used for anesthesia during surgery, stimulates glutamate development, prompting the brain to form new neural connections. This enhances the brain's adaptability and capacity to develop new pathways, aiding individuals in fostering more positive thoughts and behaviors. The Food and Drug Administration (FDA) approved esketamine, a new ketamine depression drug, in a nasal spray form for patients who have unsuccessfully tried two antidepressants before.

Major companies in the antidepressant market are strategically focusing on introducing new drugs to maximize revenue. For example, Biogen Inc and Sage Therapeutics, Inc. launched ZURZUVAE (zuranolone) in August 2023, an oral treatment for postpartum depression (PPD), addressing the underdiagnosed and undertreated condition. ZURZUVAE (zuranolone) is the first FDA-approved medication specifically designed for PPD.

In December 2023, AbbVie Inc., a pharmaceutical company based in the United States, acquired Cerevel Therapeutics Holdings, Inc. for $8.7 billion. This strategic move is intended to bolster AbbVie's ability to address complex neurological conditions and improve patient outcomes by offering enhanced therapeutic options. Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company in the U.S. that focuses on developing innovative treatments for disorders of the central nervous system (CNS).

Major companies operating in the antidepressants market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Fresenius Kabi AG, Abbott Laboratories, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Boehringer Ingelheim GmbH, H. Lundbeck AS, Teva Pharmaceutical Industries Ltd., Akeda Pharmaceutical Co., Otsuka Pharmaceutical Co., Mylan N.V, Sun Pharmaceuticals Pvt. Ltd., Servier Laboratories, Sumitomo Dainippon Pharma Co., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Allergan plc, Alkermes plc, Egis Pharmaceuticals plc, Forest Laboratories Inc.

North America was the largest region in the antidepressants market in 2024. Middle East is expected to be the largest growing region in the global antidepressants market during the forecast period. The regions covered in the antidepressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antidepressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antidepressants are medications designed to alleviate depressive symptoms, and they can also be effective in addressing seasonal affective disorder (SAD), various anxiety disorders, and social anxiety disorder. However, it's important to note that unpleasant side effects may accompany the use of antidepressants. Initially, individuals may experience common signs and symptoms such as nausea, weight gain, or disruptions in sleep patterns.

The primary categories of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs, a widely used medication type, are employed not only for treating depression but also for addressing certain other mental health conditions. The diverse range of drug classes encompasses monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants, all of which find application in treating major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder.

The antidepressants market research report is one of a series of new reports that provides antidepressants market statistics, including antidepressants industry global market size, regional shares, competitors with an antidepressants market share, detailed antidepressants market segments, market trends, and opportunities, and any further data you may need to thrive in the antidepressants industry. This antidepressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antidepressants market consists of sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.